TABLE 2.
Changes in fibrosis score and laboratory data in the sitagliptin group (n = 44) and the placebo group (n = 32) before and after the intervention.a
| Variables | Groups | Before intervention median (IQR) | After intervention median (IQR) | P-valueb |
| Insulin (Mu/L) | Sitagliptin | 13 (10, 18) | 11 (9, 16) | 0.11 |
| Placebo | 14 (11, 18) | 13 (11, 17) | 0.54 | |
| HOMA-IR | Sitagliptin | 3.53 (2.40, 4.70) | 2.93 (2.14, 4.29) | 0.09 |
| Placebo | 3.83 (2.64, 4.57) | 3.34 (2.67, 4.44) | 0.56 | |
| FBS (mg/dl) | Sitagliptin | 102 (97, 114) | 101 (97, 108) | 0.63 |
| Placebo | 107 (98, 112) | 101 (94, 108) | 0.92 | |
| Total cholesterol (mg/dl) | Sitagliptin | 189 (165, 222) | 176 (158, 205) | 0.12 |
| Placebo | 201 (174, 238) | 174 (156, 204) | 0.030 | |
| LDL-cholesterol (mg/dl) | Sitagliptin | 121 (110, 137) | 106 (92, 131) | 0.023 |
| Placebo | 125 (112, 137) | 105 (98, 135) | 0.19 | |
| HDL-cholesterol (mg/dl) | Sitagliptin | 40 (34, 45) | 40 (40, 42) | 0.72 |
| Placebo | 42 (37.0, 44.0) | 42 (40.0, 44.5) | 0.52 | |
| Triglyceride (mg/dl) | Sitagliptin | 146 (110, 201) | 136 (118, 202) | 0.18 |
| Placebo | 149 (106, 223) | 134 (102, 183) | 0.69 | |
| ALT (IU/L) | Sitagliptin | 44 (34, 70) | 40 (24, 52) | 0.036 |
| Placebo | 38 (33, 56) | 35 (30, 50) | 0.21 | |
| AST (IU/L) | Sitagliptin | 36 (28, 49) | 24 (19, 36) | < 0.001 |
| Placebo | 31 (27, 41) | 26 (20, 32) | 0.019 | |
| GGT (IU/L) | Sitagliptin | 44 (36, 55) | 42 (40, 48) | 0.43 |
| Placebo | 40 (24, 51) | 41 (35, 49) | 0.90 | |
| ALKP (IU/L) | Sitagliptin | 201 (158, 230) | 192 (156, 231) | 0.60 |
| Placebo | 176 (160, 214) | 179 (168, 198) | 0.25 | |
| Ferritin (μg/l) | Sitagliptin | 108 (38, 172) | 105 (67, 170) | 0.081 |
| Placebo | 95 (48, 217) | 66 (40, 108) | 0.22 | |
| Fibrosis score, Med (IQR) | Sitagliptin | 6.25 (5.97, 7.30) | 6.00 (5.40, 6.85) | 0.001 |
| Placebo | 6.00 (5.00, 6.93) | 5.45 (4.80, 6.30) | 0.19 |
aMedian (IQR).
bWilcoxon signed rank test with continuity correction; Wilcoxon signed rank exact test.
FBS, fasting blood sugar; HOMA-IR, homeostasis model of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.